Japanese journal of radiology · 2026
Stereotactic body radiation therapy for hepatocellular carcinoma larger than 5 cm: a systematic review and meta-analysis.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
He Jiaoling, Wang Xiurong, Zuo Tingfang, Wang Lumin, Wang Yahui, Zheng Shuping, Zhou Ruixiang, Zhang Yan
Аннотация
PURPOSE: The efficacy of stereotactic body radiation therapy (SBRT) for large (≥ 5 cm) hepatocellular carcinoma (HCC) remains unclear.
MATERIALS AND METHODS: This systematic review and meta-analysis (PROSPERO: CRD420261295276) searched six databases (Embase, PubMed, Scopus, Web of Science, Cochrane Library, and Clinical Trial databases) and included eleven studies (424 patients) evaluating SBRT for large HCC up to May 31, 2026.
RESULTS: The pooled 1- and 2-year local control rates were 81% (95% confidence interval [CI], 66-90%) and 69% (95% CI 48-84%), respectively, and the corresponding overall survival rates were 60% (95% CI 55-66%) and 37% (95% CI 30-45%). Mean/median age < 65 years was a favorable factor for 2-year overall survival (P < 0.05). Severe liver toxicity (grade ≥ 3) is rare. SBRT provides effective local control and overall survival with acceptable toxicity for large HCC.
CONCLUSION: These findings support SBRT as a viable option for patients with HCC ≥ 5 cm, although further prospective studies are warranted.
MATERIALS AND METHODS: This systematic review and meta-analysis (PROSPERO: CRD420261295276) searched six databases (Embase, PubMed, Scopus, Web of Science, Cochrane Library, and Clinical Trial databases) and included eleven studies (424 patients) evaluating SBRT for large HCC up to May 31, 2026.
RESULTS: The pooled 1- and 2-year local control rates were 81% (95% confidence interval [CI], 66-90%) and 69% (95% CI 48-84%), respectively, and the corresponding overall survival rates were 60% (95% CI 55-66%) and 37% (95% CI 30-45%). Mean/median age < 65 years was a favorable factor for 2-year overall survival (P < 0.05). Severe liver toxicity (grade ≥ 3) is rare. SBRT provides effective local control and overall survival with acceptable toxicity for large HCC.
CONCLUSION: These findings support SBRT as a viable option for patients with HCC ≥ 5 cm, although further prospective studies are warranted.